2. JAK/STAT Signaling Stem Cell/Wnt PI3K/Akt/mTOR
  3. STAT PI3K mTOR Akt
  4. Bellidifolin

Bellidifolin is an orally active compound with antiproliferative, anti-inflammatory and antioxidant properties. Bellidifolin modulates key signaling pathways including STAT3, PI3K-Akt, mTOR and BRD4, and inhibits the viral protein R (Vpr). Bellidifolin induces cell cycle arrest and apoptosis, exerts significant antifibrotic effects, and protects the heart, liver and nervous system. Bellidifolin is applicable to the research of various diseases such as lung cancer, non-alcoholic fatty liver disease, myocardial hypertrophy and ischemic cranial nerve injury.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Bellidifolin

Bellidifolin 화학구조

CAS No. : 2798-25-6

사이즈 가격 재고 수량
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 해외재고보유
Solution
10 mM * 1 mL in DMSO 해외재고보유
Solid
1 mg 해외재고보유
5 mg 해외재고보유
10 mg 해외재고보유
50 mg   견적 받기  
100 mg   견적 받기  

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

고객리뷰

Based on 1 publication(s) in Google Scholar

Bellidifolin Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Bellidifolin

View All STAT Isoform Specific Products:

View All Isoforms
STAT3 STAT5 STAT6 STAT1

View All PI3K Isoform Specific Products:

View All Isoforms
PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

View All mTOR Isoform Specific Products:

View All Isoforms
mTOR mTORC1 mTORC2

View All Akt Isoform Specific Products:

View All Isoforms
Akt Akt1 Akt2 Akt3

  • Biological Activity

  • 순도&문서

  • References

  • 고객리뷰

제품 설명

Bellidifolin is an orally active compound with antiproliferative, anti-inflammatory and antioxidant properties. Bellidifolin modulates key signaling pathways including STAT3, PI3K-Akt, mTOR and BRD4, and inhibits the viral protein R (Vpr). Bellidifolin induces cell cycle arrest and apoptosis, exerts significant antifibrotic effects, and protects the heart, liver and nervous system. Bellidifolin is applicable to the research of various diseases such as lung cancer, non-alcoholic fatty liver disease, myocardial hypertrophy and ischemic cranial nerve injury[1][2][3][4][5][6].
IC50 & Target

STAT3

 

Cellular Effect
Cell Line Type Value Description References
C6 IC50
> 100 μM
Compound: 7
Antiproliferative activity against rat C6 cells assessed as cell number after 48 hrs by crystal violet assay
Antiproliferative activity against rat C6 cells assessed as cell number after 48 hrs by crystal violet assay
[PMID: 18406151]
U-251 IC50
> 100 μM
Compound: 7
Antiproliferative activity against human U251 cells assessed as cell number after 48 hrs by crystal violet assay
Antiproliferative activity against human U251 cells assessed as cell number after 48 hrs by crystal violet assay
[PMID: 18406151]
In Vitro

Bellidifolin (25-100 μM; 72 h) potently inhibits the proliferation of human A549 lung adenocarcinoma cells in a concentration-dependent manner after 72 h, with significant inhibitory effects observed at concentrations of 50, 75, and 100 μM; however, it exerts no antiproliferative activity against normal human lung epithelial BEAS-2b cells following treatment at 25 to 100 μM for 72 h[1].
Bellidifolin (50-100 μM; 72 h) upregulates the levels of caspase-8 and caspase-3 in a dose-dependent manner, and downregulates the level of PARP1, in human A549 lung adenocarcinoma cells[1].
Bellidifolin (10-40 μM; pre-incubated for 4 h followed by 6 h of hypoxia treatment) concentration-dependently ameliorates hypoxia-induced morphological damage in PC12 cells, with the 40 μM concentration enabling near-complete recovery of cell morphology to the normal state[2].
Bellidifolin (with BRD4 overexpressed, pre-incubated for 0.5 h prior to 12 h of ISO stimulation, at an administration concentration of 30 μM) exerts anti-hypertrophic effects, restores cell viability, and inhibits ISO-stimulated Pol II phosphorylation in H9C2 cells in a BRD4-dependent manner[3].
Bellidifolin (administered following 0.5 h of pre-incubation, followed by ISO stimulation for 12 h, and conducted after Nox4 overexpression/knockdown and BRD4 overexpression) inhibits ISO-induced cardiomyocyte hypertrophy in H9C2 cells via a BRD4/Nox4-dependent pathway[3].
Bellidifolin (10 μM; 2 h pre-incubation) restores reduced anti-adipogenic protein levels in HepG2 cells, activates AMPK and inhibits mTOR phosphorylation, thereby reversing the BPF-induced upregulation of adipogenesis-related mRNAs and proteins, restoring the dysregulated AMPK-mTOR signaling axis, and suppressing the translocation of SREBP-1c from the cytoplasm to the nucleus[4].
Bellidifolin (12.5-50 μM; 24 h) reduces the expression levels of TGF-β1-induced α-SMA, Collagen I and Collagen III proteins, and inhibits TGF-β1-induced SOX9 expression and Smad3 phosphorylation in human cardiac fibroblasts[5].
Bellidifolin (20-80 μM; 12 h) alters the gene expression of H9c2 cells subjected to H2O2-induced injury, with its differentially expressed genes (DEGs) enriched in pathways including the PI3K-Akt signaling pathway[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Bellidifolin Related Antibodies

Cell Proliferation Assay[1]

Cell Line: human A549 lung adenocarcinoma cells, human normal lung epithelial BEAS-2b cells
Concentration: 25 μM, 50 μM, 75 μM, 100 μM
Incubation Time: 72 h
Result: Exhibited a time- and concentration-dependent inhibitory effect on proliferation in A549 cells, with significantly more evident growth inhibition at 50, 75, and 100 μM compared to 25 μM.
Caused no cytotoxic or antiproliferative effect in BEAS-2b cells at 25, 50, 75, and 100 μM.

Cell Viability Assay[2]

Cell Line: pheochromocytoma (PC12) cells
Concentration: 10-40 μM (pre-incubated)
Incubation Time: 4 h (pre-incubation); 6 h (hypoxia exposure)
Result: Significantly increased PC12 cell viability to 70.28 ± 4.00% compared to hypoxia alone at 20 μM.
Restored cell viability to near-control levels (85.30 ± 2.45%), which was significantly elevated compared to hypoxia alone, at 40 μM.

Western Blot Analysis[5]

Cell Line: TGF-β1-stimulated human cardiac fibroblasts (HCFs)
Concentration: 12.5-50 μM (co-incubated with TGF-β1)
Incubation Time: 24 h
Result: Significantly downregulated the TGF-β1-induced increases in α-SMA, Collagen I, and Collagen III protein expression.\nPrevented TGF-β1-induced elevations in SOX9 protein expression.
Reduced TGF-β1-induced Smad3 phosphorylation.
In Vivo

Bellidifolin exerts significant protective effects against focal cerebral ischemic injury in rats by inhibiting oxidative stress, reducing excitatory amino acid levels, and increasing GABA content[2].
Bellidifolin (30 mg/kg/day; p.o.; daily; 21 consecutive days) ameliorates isoprenaline-induced cardiac hypertrophy in Kunming mice by inhibiting the BRD4/Nox4/ROS signalling pathway, significantly reducing cardiac hypertrophy markers, pathological changes, and restoring cardiac function[3].
Bellidifolin (100 mg/kg body weight; i.p.; once daily; 14 days) mitigates BPF-induced nonalcoholic fatty liver disease-like changes in male C57BL/6J mice by activating AMPK, inhibiting mTOR, and downregulating lipogenesis-associated proteins[4].
Bellidifolin (25-50 mg/kg; p.o.; daily; 21 days) ameliorates isoproterenol-induced myocardial fibrosis in Kunming mice by inhibiting SOX9 expression, which in turn reduces the expression of α-SMA, Collagen I, and Collagen III[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Kunming (male, 8-10 weeks old, 18-22 g, isoprenaline-induced cardiac hypertrophy)[3]
Dosage: 30 mg/kg/day
Administration: p.o.; daily; 21 consecutive days
Result: Significantly reduced increases in ejection fraction (EF) and fractional shortening (FS).
Reversed increases in left ventricular diastolic anterior wall thickness (LVAWd) and left ventricular systolic anterior wall thickness (LVAWs).
Increased left ventricular end-systolic diameter (LVESD).
Reduced cardiomyocyte disarray, collagen deposition, and cardiomyocyte cross-sectional area.
Significantly decreased protein levels of ANP and BNP, and mRNA levels of ANP, BNP, and β-MHC.
Reduced isoprenaline-induced elevation of BRD4 protein and mRNA levels.
Decreased H3K122 acetylation and RNA Pol II phosphorylation.
Reduced Nox4 protein and mRNA levels, decreased intracellular ROS levels, and reduced mRNA levels of ADAM17 and TNF-α.
Animal Model: C57BL/6J (male, 5 to 6 weeks old, NAFLD induced by bisphenol F gavage)[4]
Dosage: 100 mg/kg body weight
Administration: i.p.; once daily; 14 days
Result: Significantly reduced BPF-induced hepatic lipid deposition, as shown by decreased Oil Red O staining intensity.
Normalized BPF-increased liver triglyceride and total cholesterol levels.
Reversed BPF-induced upregulation of lipogenesis-associated proteins (ACC, FAS, SREBP-1c, C/EBPα, PPARγ, SCD1) in mouse liver.
Restored BPF-reduced AMPK phosphorylation and inhibited BPF-increased mTOR phosphorylation in mouse liver.
Animal Model: Kunming (male; isoproterenol-induced myocardial fibrosis model)[5]
Dosage: 25 mg/kg; 50 mg/kg
Administration: p.o.; daily; 21 days
Result: Significantly improved ISO-induced histopathological myocardial changes, including reducing myocardial fiber disorganization, degeneration, necrosis, and inflammatory cell infiltration.
Significantly reduced ISO-induced collagen deposition in cardiac tissue.
Prevented ISO-induced elevations in the fibrosis-related proteins α-SMA, Collagen I, and Collagen III, as measured by Western blot and immunohistochemistry.
Significantly decreased ISO-induced increases in SOX9 protein expression in cardiac tissue.
Achieved statistically significant reductions relative to the ISO model group for all measured endpoints.
분자량

274.23

화학식

C14H10O6
CAS No.
Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C1C2=C(OC3=C1C(O)=CC=C3O)C=C(OC)C=C2O
Structure Classification
Initial Source
선적

Room temperature in continental US; may vary elsewhere.
보관

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

용액&용해도
In Vitro: 

DMSO : 50 mg/mL (182.33 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.6466 mL 18.2329 mL 36.4657 mL
5 mM 0.7293 mL 3.6466 mL 7.2931 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • 몰농도 계산기

  • 농도 희석 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
순도&문서

Purity: 99.74%

SDS (393 KB)

COA (252 KB) HNMR (245 KB) LCMS (88 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.6466 mL 18.2329 mL 36.4657 mL 91.1643 mL
5 mM 0.7293 mL 3.6466 mL 7.2931 mL 18.2329 mL
10 mM 0.3647 mL 1.8233 mL 3.6466 mL 9.1164 mL
15 mM 0.2431 mL 1.2155 mL 2.4310 mL 6.0776 mL
20 mM 0.1823 mL 0.9116 mL 1.8233 mL 4.5582 mL
25 mM 0.1459 mL 0.7293 mL 1.4586 mL 3.6466 mL
30 mM 0.1216 mL 0.6078 mL 1.2155 mL 3.0388 mL
40 mM 0.0912 mL 0.4558 mL 0.9116 mL 2.2791 mL
50 mM 0.0729 mL 0.3647 mL 0.7293 mL 1.8233 mL
60 mM 0.0608 mL 0.3039 mL 0.6078 mL 1.5194 mL
80 mM 0.0456 mL 0.2279 mL 0.4558 mL 1.1396 mL
100 mM 0.0365 mL 0.1823 mL 0.3647 mL 0.9116 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Bellidifolin Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Bellidifolin2798-25-6STATPI3KmTORAktPhosphoinositide 3-kinaseMammalian target of RapamycinPKBProtein kinase BBEAS-2b cellsCOX-2BRD4AMPKSTAT3PC12 cellsA549 lung adenocarcinoma cellsNox4H9C2 cellsInhibitorinhibitorinhibit

최근 본 상품:

온라인 문의

Your information is safe with us. * Required Fields.

상품명

  

Requested Quantity *

고객명 *

 

호칭

메일주소 *

 

전화번호 *

Department

 

회사명 *

City

도

Country or Region *

      

비고

대량구매 문의

Inquiry Information

상품명:
Bellidifolin
Cat. No.:
HY-N2000
수량:
MCE Japan Authorized Agent:

고객리뷰

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

상품명

  

Lot #

고객명 *

 

메일주소 *

전화번호

 

Department *

회사명 *

 

Country or Region *

비고

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.